Matrix-FBG-enhanced wound repair is dependent on integrin activation and active assembly of FN and FBG in the ECM. (A) HFFs were treated with 40 μg/mL FBG-Oregon Green plus 10 μg/mL either nonimmune IgG1 (i,iv), anti-αvβ3 (LM609; ii,v), or 2 μg/mL anti-FN-III1 (9D2; iii,vi) IgG1 for 24 hours. (A) The intensity and pattern of FN fibrils was detected by indirect immunofluorescence (i-iii), and FBG-Oregon Green assembled into matrix fibrils was visualized by direct epifluorescence (iv-vi). Scale bar represents 25 μm. (B) Fibroblasts treated with nonlabeled FBG and nonimmune IgG1, LM609 (anti-αvβ3), or 9D2 (anti-FN-III1) MoAb were wounded, and the number of cells migrating into the denuded space over 16 hours was quantified as described in “Materials and methods.” The data are presented as the mean ± SEM; n = 4 to 6 per condition from 3 separate experiments. (C) The effect of antibody treatment on wound closure was visualized by staining F-actin and low-power microscopy in CONTROL cells (i-iii) and FBG-PRE-treated cells (iv-vi). Scale bar represents 40 μm.
